✦ LIBER ✦

Biostatistics in nonclinical and preclinical drug development

✍ Scribed by L. A. Hothorn

Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 61 KB
Volume: 47
Category: Article
ISSN: 0323-3847
DOI: 10.1002/bimj.200510128

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Proteomics: Applications and opportuniti

Proteomics: Applications and opportunities in preclinical drug development

✍ Sandra Steiner; Frank A. Witzmann 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB 👁 1 views

Principles of CNS Drug Development || Pr

Principles of CNS Drug Development || Preclinical and Clinical Safety Evaluation

✍ Kelly, John 📂 Article 📅 2010 🏛 John Wiley & Sons, Ltd ⚖ 313 KB 👁 2 views

Nonclinical support of pediatric drug de

Nonclinical support of pediatric drug development in a global context: an industry perspective

✍ Gregg D. Cappon 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB

Preclinical safety evaluations supportin

Preclinical safety evaluations supporting pediatric drug development with biopharmaceuticals: strategy, challenges, current practices

✍ LaRonda L. Morford; Christopher J. Bowman; Diann L. Blanset; Ingrid B. Bøgh; Gar 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 466 KB

Role of drug metabolism in drug research

Role of drug metabolism in drug research and development

✍ Sidney S. Walkenstein 📂 Article 📅 1972 🏛 John Wiley and Sons 🌐 English ⚖ 67 KB 👁 1 views

Role of drug metabolism in drug discover

Role of drug metabolism in drug discovery and development

✍ Gondi N. Kumar; Sekhar Surapaneni 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 300 KB 👁 1 views

## Abstract Metabolism by the host organism is one of the most important determinants of the pharmacokinetic profile of a drug. High metabolic lability usually leads to poor bioavailability and high clearance. Formation of active or toxic metabolites will have an impact on the pharmacological and t